Industry News

Lupin Limited announced the achievement of key milestones for Lupins MEK inhibitor compound (LNP3794) that is planned for development by Boehringer Ingelheim in combination as potential targeted therapy for patients with difficult-to-treat cancers.

As part of the agreement, Lupin has received payment of USD 50 million from Boehringer Ingelheim
for achievement of key milestones.

Moderna, Inc a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.

Roche India and Cipla Limited announced that the first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product by leveraging its strong distribution strengths across the country. The drug will be available through leading hospitals and COVID treatment centers.

Zydus Cadila, a global innovation driven healthcare company, launched Trastuzumab Emtansine, the first Antibody Drug Conjugate (ADC) biosimilar and a highly effective drug for treating both Early and Advanced HER2 positive Breast Cancer, under the brand name Ujvira. HER2 positive Breast Cancer is considered an aggressive form and constitutes 20 to 25% of all Breast Cancers.

Pfizer Inc that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyxs lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.

Syngene International, an integrated research, development and manufacturing services company, announced that it has extended its ongoing research collaboration with Bristol Myers Squibb. The collaboration has been extended through the end of 2030 and will expand the breadth of drug discovery research conducted, including chemistry, biology, drug metabolism and pharmacokinetics, as well as translational medicine research and pharmaceutical development, including chemical process development and analytical sciences, in the coming years.

US-India Strategic Partnership Forum and members appreciate the efforts by leaders across the U.S. government at the highest level to identify concrete steps the United States can take to assist India through this crisis. The company looks forward to announcements soon that will support India’s efforts to fill needs like oxygen, medicines, medical supplies, and vaccines. This should include a waiver of current restrictions on the export of vaccine raw materials to ensure production of vaccine in India can continue uninterrupted.

Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride Extended- Release Capsules USP, 225 mg, 325 mg, and 425 mg (US RLD: Rythmol Capsules). Propafenone is known as an anti-arrhythmic drug. It works by blocking the activity of certain electrical signals in the heart that can cause an irregular heartbeat.